---
title: "Agenus Inc. Reports No Material Changes to Previously Disclosed Risk Factors in Latest Review"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295365390.md"
description: "Agenus Inc. (AGEN) disclosed a new risk under the Regulation category but reported no material changes to its previously disclosed risk factors in its latest review of the Form 10-K for the year ended December 31, 2025. This indicates the company's overall risk profile remains largely unchanged. Wall Street maintains a Moderate Buy consensus rating on AGEN stock based on two buy recommendations."
datetime: "2026-08-10T06:01:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295365390.md)
  - [en](https://longbridge.com/en/news/295365390.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295365390.md)
generator: "portal-rs"
---

# Agenus Inc. Reports No Material Changes to Previously Disclosed Risk Factors in Latest Review

Agenus Inc. (AGEN) has disclosed a new risk, in the Regulation category.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Agenus Inc. faces ongoing exposure to the broad array of risks and uncertainties already detailed in its Form 10-K for the year ended December 31, 2025. An external review indicates that, during the current period, there have been no material changes to those previously disclosed risk factors, suggesting the company’s risk profile remains largely unchanged.

Overall, Wall Street has a Moderate Buy consensus rating on AGEN stock based on 2 Buys.

To learn more about Agenus Inc.’s risk factors, click here.

### Related Stocks

- [AGEN.US](https://longbridge.com/en/quote/AGEN.US.md)
- [00847G804.US](https://longbridge.com/en/quote/00847G804.US.md)

## Related News & Research

- [Agenus reports 21.2-month median survival in Phase 1b BOT+BAL study for MSS metastatic colorectal cancer](https://longbridge.com/en/news/297338792.md)
- [Agenus reports no recurrences in Phase 2 NEST trial of botensilimab plus balstilimab in resectable colon cancer](https://longbridge.com/en/news/297058971.md)
- [How F5’s Expanded AI Security Features Could Reshape Its Role for Investors (FFIV)](https://longbridge.com/en/news/297753890.md)
- [Is Cloudflare’s (NET) New Adaptive Intelligence Shaping a Defensible Edge in Bot Security?](https://longbridge.com/en/news/297622337.md)
- [17:02 ETEl sistema de seguridad Veeva Falcon funciona con todos los sistemas de seguridad compatibles con E2B](https://longbridge.com/en/news/297699152.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**